Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
Snakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-02-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005361&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716927550717952 |
|---|---|
| author | Andreas H Laustsen Kristoffer H Johansen Mikael Engmark Mikael R Andersen |
| author_facet | Andreas H Laustsen Kristoffer H Johansen Mikael Engmark Mikael R Andersen |
| author_sort | Andreas H Laustsen |
| collection | DOAJ |
| description | Snakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not only on their possible therapeutic impact, but also on their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better snakebite envenoming therapies. Based on industry data, the cost of treatment for a snakebite envenoming with a recombinant antivenom is estimated to be in the range USD 60-250 for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers) currently on the market has been reported to have a wholesale price of USD 640 per treatment for an average snakebite. Recombinant antivenoms may therefore in the future be a cost-competitive alternative to existing serum-based antivenoms. |
| format | Article |
| id | doaj-art-dd237e67f47b4d76a9b98ac61d9010cc |
| institution | DOAJ |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2017-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-dd237e67f47b4d76a9b98ac61d9010cc2025-08-20T03:12:50ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-02-01112e000536110.1371/journal.pntd.0005361Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?Andreas H LaustsenKristoffer H JohansenMikael EngmarkMikael R AndersenSnakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not only on their possible therapeutic impact, but also on their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better snakebite envenoming therapies. Based on industry data, the cost of treatment for a snakebite envenoming with a recombinant antivenom is estimated to be in the range USD 60-250 for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers) currently on the market has been reported to have a wholesale price of USD 640 per treatment for an average snakebite. Recombinant antivenoms may therefore in the future be a cost-competitive alternative to existing serum-based antivenoms.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005361&type=printable |
| spellingShingle | Andreas H Laustsen Kristoffer H Johansen Mikael Engmark Mikael R Andersen Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? PLoS Neglected Tropical Diseases |
| title | Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? |
| title_full | Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? |
| title_fullStr | Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? |
| title_full_unstemmed | Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? |
| title_short | Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? |
| title_sort | recombinant snakebite antivenoms a cost competitive solution to a neglected tropical disease |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005361&type=printable |
| work_keys_str_mv | AT andreashlaustsen recombinantsnakebiteantivenomsacostcompetitivesolutiontoaneglectedtropicaldisease AT kristofferhjohansen recombinantsnakebiteantivenomsacostcompetitivesolutiontoaneglectedtropicaldisease AT mikaelengmark recombinantsnakebiteantivenomsacostcompetitivesolutiontoaneglectedtropicaldisease AT mikaelrandersen recombinantsnakebiteantivenomsacostcompetitivesolutiontoaneglectedtropicaldisease |